



Working together for a healthier world™

## Pfizer's Safe Sharps Disposal Plan

In accordance with Senate Bill 486, codified within Public Resources Code, Chapter 1 of Part 7 of Division 30, Sections 47115-47116, and Laws of Minnesota 2010, Chapter 286, Senate File No. 1323, Pfizer is pleased to submit this report, which describes the Company's current sharps disposal support provided to patients who self-inject Pfizer medicines at home, and our plans for next year. As required, [this report has been posted to Pfizer's public website](#).

As background for public readers of this report, the California Legislature passed and the governor signed SB 486 in October 2009. The bill requires, on or before July 1, 2010, and annually thereafter, a pharmaceutical manufacturer that sells or distributes medication that is self-injected at home through the use of hypodermic needles and other similar devices (i.e., sharps) to submit to CalRecycle a plan that describes how the manufacturer supports the safe collection and proper disposal of the used sharps.

The Minnesota legislature signed by the governor April 30, 2010, also requires Pfizer to post to its website how the company supports the safe collection and proper disposal of sharps.

### Highlights

- Pfizer provides information to patients for one on one instruction for all its self-injecting patients for all its self-injected products, nationwide.
- Pfizer provides information to patients to help them understand how to safely dispose of their injection devices, and the state and local requirements for sharps disposal, nationwide.
- Patients have multiple options to get sharps disposal questions answered, and get assistance in finding a local disposal option nationwide.
- Pfizer is innovating, by offering safer injection devices or reducing the number of sharps needed to administer its medicines.
- Pfizer supports the Coalition for Community Safe Needle Disposal, and its efforts to ensure patients can find the latest information on local, regional, and state sharps disposal programs.

Pfizer has ten products that are self-injected by patients in the home. Six of the products are biopharmaceuticals (BeneFix, Enbrel, Genotropin, Rebif, Somavert, and Xyntha) that are provided to patients through specialty pharmacies, which are

specially equipped to store and ship the medicines to patients properly (often they are refrigerated or frozen). One product, (Alsuma) is currently marketed in the US only. The remaining three products are older products that are or will soon face generic competition (Caverject and Neumega), and a Pfizer-generic product (Epinephrine Injection, USP).

## **General Sharps Management**

It is Pfizer's policy to customize our support uniquely to the characteristics of each product and its patients' needs; therefore, the sharps disposal support will likely differ product by product. However the following general provisions apply throughout the portfolio.

## **Provider, Patient and User Education**

Doctors, nurse trainers, call center staff and patients have access to [www.safeneedledisposal.org](http://www.safeneedledisposal.org) via Pfizer's product stewardship website. This site has an up-to-date summary of state sharps disposal requirements, with links to state programs.

All users of injectable medicines for use at home are given advice and guidance on the safe disposal of used and expired medicines by trained healthcare providers when they receive their medicines.

All product inserts advise the patient to dispose of sharps in a responsible and appropriate manner in line with the guidance as provided by the healthcare provider

Pfizer provides product specific toll free patient support numbers that provide additional support and guidance around sharps disposal. Information can also be found on [Pfizer's Product Stewardship website](#).

## **Product Programs & Innovation**

Pfizer is working towards providing a comprehensive sharps management and disposal program, in line with this aim a number of products already have specific initiatives and technologies in place. During 2011 work is underway to build upon these efforts.

## **Genotropin<sup>®</sup> / Somavert<sup>®</sup>**

For eligible patients the take back of Genotropin<sup>®</sup> and Somavert<sup>®</sup> medicines is available through the Pfizer Bridge Program<sup>®</sup>. Each old device can be exchanged and disposed of free of charge by calling the Pfizer Bridge toll free number.

## **Alsuma™**

The Alsuma™ Auto-Injector is supplied with a number of features that assist in the safe use and disposal of this treatment.

- Each Auto-Injector is provided to the patient with an individual storage and disposal case designed to prevent damage to the injector and inadvertent contact
- The injector itself is designed with a retractable needle which further prevents inadvertent contact with the needle

## **Enbrel**

Enbrel is offered in a single-use, auto-injector that can be considered a safe needle device because the needle retracts into the device after use.

## **Sharps Disposal Support Plans for 2011-2012**

The majority of Pfizer medicines that are self-injected at home reach patients through specialty pharmacies, which are specially equipped to store and ship the biopharmaceutical medicines properly to patients. Pfizer has reached out to several pharmacy trade associations in the hope of finding a means of reaching, on a national basis, this subset of patient pharmacies. In 2011, we would like to explore if a sharps management program could be arranged through them that would be convenient to patients and be cost effective, and develop the scope of a pilot program to be implemented in 2012, if a program indeed is deemed practical.

The product inserts associated with Pfizer's self-injected products currently provide correct and detailed sharps disposal instructions. However, the language is not consistent between all products and devices. Pfizer is planning to revise the sharps disposal language in all product inserts to assure consistent messaging, but as those product inserts require modification for other reasons, Pfizer expects this process to take a few years.

For any questions regarding this report, please feel free to contact +212-573-7356